Lanthanum Carbonate

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Lanthanum Carbonate
   1. Pharmacist Assessment Report
   2. Lanthanum Carbonate: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Lanthanum Carbonate: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Lanthanum Carbonate, so there is currently no new predicted indication. The drug’s recorded uses are listed below; none are recorded for this drug at present.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	0
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
13874F	Fosrenol	Tablet, chewable, 1000 mg (as carbonate	Valid

Safety Considerations

• Gut-related contraindication signals (knowledge graph, not label text): ileus, intestinal obstruction, constipation disorder and intestinal impaction.
• Drug Interactions: 76 interactions were identified. The 20 listed in the data compiled for this report are all rated Moderate. They include:
  • Tetracycline-class antibiotics: doxycycline, minocycline, tetracycline.
  • Fluoroquinolones: levofloxacin, ciprofloxacin, delafloxacin.
  • Bisphosphonates: alendronic acid, risedronic acid.
  • Beta-blockers: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol.
  • ACE inhibitors: benazepril, captopril, enalapril.
  • Others: iron, chloroquine, digoxin, valproic acid.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---